- Home
- JLS vs COYA Comparison
JLS vs COYA Comparison
Compare JLS & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | JLS | COYA |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 94.1M | 110.0M |
| IPO Year | 2009 | 2022 |
Fundamental Metrics
Financial Performance| Metric | JLS | COYA |
|---|---|---|
| Price | $17.11 | $4.67 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $15.80 |
| AVG Volume (30 Days) | 22.3K | ★ 146.4K |
| Earning Date | 01-01-0001 | 05-08-2026 |
| Dividend Yield | ★ 9.33% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $7,945,753.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $763.10 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 123.57 |
| 52 Week Low | $17.10 | $3.71 |
| 52 Week High | $19.09 | $7.75 |
Technical Indicators
Market Signals| Indicator | JLS | COYA |
|---|---|---|
| Relative Strength Index (RSI) | 35.40 | 51.44 |
| Support Level | N/A | $4.45 |
| Resistance Level | $18.72 | $5.18 |
| Average True Range (ATR) | 0.13 | 0.23 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 7.50 | 84.92 |
Price Performance
Historical ComparisonAbout JLS Nuveen Mortgage and Income Fund
Nuveen Mortgage And Income Fund is a diversified, closed-end management investment company. The fund invests at least fifty percent of its Managed Assets in MBS, including residential MBS and commercial MBS, and up to fifty percent in non-mortgage related ABS. The Fund's investment objective is to provide a high level of current income.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary new therapies to enhance the function of regulatory T cells (Tregs). The company's initial development programs are focused on neurodegenerative, chronic inflammatory, autoimmune, and metabolic diseases with high unmet medical needs.